A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

NCT01308762 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Heat killed whole cell M. obuense (IMM-101) 0.1 mg
BIOLOGICAL: Heat-killed whole cell M.obuense (IMM-101) 0.5 mg
BIOLOGICAL: Heat killed whole cell M.obuense (IMM-101) 1.0 mg

Sponsor

Immodulon Therapeutics Ltd

Collaborators

[object Object]
[object Object]